Composition, form of production and packaging
Concentrate for the preparation of a solution for infusions is colorless or slightly greenish, transparent.
vinpocetine 5 mg
Excipients: ascorbic acid - 0.5 mg, sodium disulfite - 1 mg, tartaric acid - 10 mg, benzyl alcohol - 10 mg, sorbitol - 80 mg, water d / and - up to 1 ml.
2 ml - dark glass ampoules (5) - plastic pallets (2) - cardboard packs.
5 ml - dark glass ampoules (5) - plastic pallets (2) - cardboard packs.
10 ml - ampoules of dark glass (5) - plastic pallets (1) - cardboard packs.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2016.
A drug that improves cerebral circulation and brain metabolism.
Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; strengthening glucose transport to the brain, through the BBB; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca 2+ -dependent phosphodiesterase; increases the levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain. Increases the concentration of ATP in the brain tissues; enhances the metabolism of noradrenaline and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.
Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the oxygen release of red blood cells.
Strengthens the neuroprotective effect of adenosine.
Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the systemic blood circulation (BP, minute volume, heart rate, OPSS).
Does not have the effect of "stealing", increases blood supply, especially in ischemic areas of the brain with low perfusion.
The therapeutic concentration in plasma is 10-20 ng / ml. For parenteral administration, V d is 5.3 l / kg. Easily penetrates through gistogematicheskie barriers (including GEB).
T 1/2 is 4.74-5 hours. It is excreted with the kidneys and through the gastrointestinal tract in a ratio of 3: 2.
- decrease in the severity of neurological and mental symptoms in various forms of cerebral circulatory insufficiency (ischemic stroke, restorative stage of hemorrhagic stroke, consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, cerebral atherosclerosis, posttraumatic and hypertensive encephalopathy);
- Chronic vascular diseases of the choroid and retina (eg, thrombosis / occlusion / central artery or retinal vein);
- for treatment of perceptual hearing loss, Meniere's disease, idiopathic tinnitus.
The drug is intended for intravenous drip infusion. Enter slowly, the rate of infusion should not exceed 80 drops / min.
Do not enter in / m and / in without dilution.
For the preparation of infusion, physiological saline or solutions containing dextrose (Salsol, Ringer, Rindex, Reomacrodex) can be used. Infusion solution with Cavinton should be used within the first 3 hours after preparation.
The usual initial daily dose is 20 mg in 500 ml of the infusion solution. Depending on the tolerability, within 2-3 days the dose can be increased to no more than 1 mg / kg / day. The average duration of treatment is 10-14 days.
The average daily dose at a body weight of 70 kg is 50 mg (in 500 ml infusion solution).
With liver and kidney disease, dose adjustment is not required.
At the end of the course in / in therapy, it is recommended to continue treatment with Cavinton В® Forte tablets (1 tablet 3 times / day) or Cavinton В® (2 tablets 3 times / day).
Side effects on the background of the use of the drug were rarely detected.
From the cardiovascular system: ECG change (ST depression, QT interval prolongation), tachycardia, extrasystole (causal connection with taking the drug is not proved, as in the natural population these symptoms are observed with the same frequency); a change in blood pressure (often a decrease), redness of the skin, phlebitis.
From the side of the central nervous system: sleep disturbances (insomnia, increased drowsiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease).
On the part of the digestive system: dry mouth, nausea, heartburn.
Other: skin allergic reactions, increased sweating.
- acute phase of hemorrhagic stroke;
- severe form of ischemic heart disease;
- severe arrhythmias;
- lactation period;
- age under 18 years (due to insufficient data);
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The drug is contraindicated in pregnancy and lactation.
The presence of the syndrome of the prolonged QT interval and the use of drugs that cause prolongation of the QT interval requires periodic monitoring of the ECG.
Infusion solution of Cavinton В® contains sorbitol (160 mg / 2 ml), therefore, in the presence of diabetes it is necessary to periodically check the blood glucose level.
In case of fructose intolerance or a deficiency of fructose 1,6-diphosphatase, vinpocetine should be avoided.
Impact on the ability to drive vehicles and manage mechanisms
There is no information on the effect of vinpocetine on the ability to drive and work machinery.
Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.
With simultaneous use, no interaction with beta-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol or hydrochlorothiazide is observed.
In rare cases, concomitant use with alpha-methyldopa is accompanied by some increase in the hypotensive effect, when using this combination, regular monitoring of blood pressure is necessary.
Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central action and antiarrhythmics.
Cavinton В® in the form of a concentrate for the preparation of a solution for infusions and heparin are chemically incompatible, so they are not allowed to be administered in the same infusion mixture, however, anticoagulants and vinpocetine can be treated concurrently.
Cavinton В® in the form of a concentrate for the preparation of a solution for infusions is incompatible with infusion solutions containing an amino acid, so they can not be used to dilute Cavinton.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, protected from light at a temperature of no higher than 25 В° C. Shelf life - 5 years. Do not use after the expiration date printed on the package.